Literature DB >> 34396408

Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection.

Kristie L Connolly1, Michelle Pilligua-Lucas1, Carolina Gomez1, Allison C Costenoble-Caherty1, Anthony Soc1, Knashka Underwood1, Andrew N Macintyre2, Gregory D Sempowski2, Ann E Jerse1.   

Abstract

Murine models of Neisseria gonorrhoeae lower reproductive tract infection are valuable systems for studying N. gonorrhoeae adaptation to the female host and immune responses to infection. These models have also accelerated preclinical testing of candidate therapeutic and prophylactic products against gonorrhea. However, because N. gonorrhoeae infection is restricted to the murine cervicovaginal region, there is a need for an in vivo system for translational work on N. gonorrhoeae pelvic inflammatory disease (PID). Here we discuss the need for well-characterized preclinical upper reproductive tract infection models for developing candidate products against N. gonorrhoeae PID, and report a refinement of the gonorrhea mouse model that supports sustained upper reproductive tract infection. To establish this new model for vaccine testing, we also tested the licensed meningococcal 4CMenB vaccine, which cross-protects against murine N. gonorrhoeae lower reproductive tract infection, for efficacy against N. gonorrhoeae in the endometrium and oviducts following transcervical or vaginal challenge. Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Entities:  

Keywords:  PID; antibiotics; gonorrhea; mouse; reproductive tract; vaccine; vaginal microbicides

Mesh:

Substances:

Year:  2021        PMID: 34396408      PMCID: PMC8365121          DOI: 10.1093/infdis/jiab211

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  50 in total

1.  Roxithromycin treatment of mouse chlamydial salpingitis and protective effect on fertility.

Authors:  J Zana; M Muffat-Joly; D Thomas; J Orfila; J Salat-Baroux; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Bacterial vaginosis: a review on clinical trials with probiotics.

Authors:  Paola Mastromarino; Beatrice Vitali; Luciana Mosca
Journal:  New Microbiol       Date:  2013-06-30       Impact factor: 2.479

Review 3.  Pelvic inflammatory disease.

Authors:  Robert C Brunham; Sami L Gottlieb; Jorma Paavonen
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

4.  Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.

Authors:  Victoria J Savage; Cédric Charrier; Anne-Marie Salisbury; Helen Box; Nathan Chaffer-Malam; Anthony Huxley; Ralph Kirk; Gary M Noonan; Sarfraz Mohmed; Mark W Craighead; Andrew J Ratcliffe; Stuart A Best; Neil R Stokes
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

5.  Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model.

Authors:  Kristie L Connolly; Ann E Eakin; Carolina Gomez; Blaire L Osborn; Magnus Unemo; Ann E Jerse
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

6.  Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.

Authors:  Michelle M Butler; Samanthi L Waidyarachchi; Kristie L Connolly; Ann E Jerse; Weirui Chai; Richard E Lee; Stephan A Kohlhoff; Dean L Shinabarger; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections.

Authors:  Ann E Jerse; Hong Wu; Mathanraj Packiam; Rachel A Vonck; Afrin A Begum; Lotisha E Garvin
Journal:  Front Microbiol       Date:  2011-07-01       Impact factor: 5.640

Review 8.  Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.

Authors:  Helen Petousis-Harris; Fiona J Radcliff
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

9.  Could Dampening Expression of the Neisseria gonorrhoeae mtrCDE-Encoded Efflux Pump Be a Strategy To Preserve Currently or Resurrect Formerly Used Antibiotics To Treat Gonorrhea?

Authors:  Shaochun Chen; Kristie L Connolly; Corinne Rouquette-Loughlin; Alexander D'Andrea; Ann E Jerse; William M Shafer
Journal:  mBio       Date:  2019-08-13       Impact factor: 7.867

10.  Biological feasibility and importance of a gonorrhea vaccine for global public health.

Authors:  Leah R Vincent; Ann E Jerse
Journal:  Vaccine       Date:  2018-04-18       Impact factor: 3.641

View more
  1 in total

Review 1.  Tissue Models for Neisseria gonorrhoeae Research-From 2D to 3D.

Authors:  Motaharehsadat Heydarian; Eva Rühl; Ravisha Rawal; Vera Kozjak-Pavlovic
Journal:  Front Cell Infect Microbiol       Date:  2022-02-11       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.